Glück R
Swiss Serum & Vaccine Institute, Berne.
Biologicals. 1994 Dec;22(4):347-51. doi: 10.1006/biol.1994.1053.
Efforts to develop new vaccine combining as many immunogens as possible have stimulated researchers of most European vaccine manufacturers to contribute with new vaccine designs. Besides the conventional combinations the following approaches are under development: new carrier systems for inactivated antigens; new adjuvants for subunit antigens; live attenuated combined vaccines; vector combined vaccines; synthetic polypeptide combined vaccines. The availability of new combined vaccines will greatly facilitate immunization programmes for the control of many diseases around the world. The whole of modern society in general is moving towards prevention--for example on safety issues--as well as in medicine, where prophylactic approaches are medically, scientifically, ethically, and mortally more justifiable as well as being more cost-effective. Besides improving the health and overall quality of life of the world's population, the use of combined vaccines will further reduce already overstretched health care budgets.
研发尽可能包含多种免疫原的新型疫苗的努力，促使大多数欧洲疫苗生产商的研究人员贡献新的疫苗设计。除了传统组合外，以下方法也在研发中：用于灭活抗原的新型载体系统；用于亚单位抗原的新型佐剂；减毒活联合疫苗；载体联合疫苗；合成多肽联合疫苗。新型联合疫苗的出现将极大地促进全球许多疾病防控的免疫规划。整个现代社会总体上都在朝着预防方向发展——例如在安全问题上——在医学领域也是如此，预防性方法在医学、科学、伦理和死亡率方面更具合理性，而且成本效益更高。除了改善世界人口的健康和整体生活质量外，联合疫苗的使用还将进一步减少已经不堪重负的医疗保健预算。
